Table 2 CSF parameters of 41 patients undergoing therapeutic apheresis (Freiburg study group)
CSF analysis | ||||
|---|---|---|---|---|
Prior to treatment | One day after treatment | Two days after treatment | More than two days after treatment (median 14.0 days; range 3–55; SD 13.5) | |
n (%) | 33 (80.5) | 19 (46.3) | 4 (9.8) | 18 (43.9) |
Intrathecal IgG synthesis, n (%) | 0 (0.0) | 9 (47.4) | 0 (0.0) | 0 (0.0) |
Intrathecal IgA synthesis, n (%) | 1 (3.1) | 7 (36.8) | 0 (0.0) | 0 (0.0) |
Intrathecal IgM synthesis, n (%) | 1 (3.1) | 8 (42.1) | 0 (0.0) | 0 (0.0) |
IgG index ≥ 0.65, n (%) | 6 (18.8) | 18 (94.7) | 1 (25.0) | 1 (5.6) |
OCBs predominantly in CSF, n (%) | 1 (3.1) | 0 (0.0) | 0 (0.0) | 1 (5.6) |